Pralsetinib
Sep 11, 2020•12 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
We have a new drug, pralsetinib, to discuss. It's the 2nd RET inhibitor approved for RET-fusion (+) metastatic NSCLC.
For the best experience, listen in Metacast app for iOS or Android